Sidley advised Vivo Capital and AdvanTech Capital as lead investors in the US$75 million Series A financing for Ablaze Pharmaceuticals (Ablaze), with participation from other institutional investors.
Vivo Capital is a leading global healthcare investment firm with a diverse, multi-fund investment platform in venture capital, growth equity, buyout, and public equities. AdvanTech Capital is a private equity fund, focused on innovation-driven growth capital in China and focuses on healthcare and TMT sectors. Ablaze is a clinical-stage pharmaceutical company focused on the development and commercialization of innovative targeted radiopharmaceutical therapies (TRT) against tumor targets.
The Sidley team was led by partner Ruchun Ji, with the support of associates Rui Liu, Longbo Wang, and Jean Qiu.
Sidley provides multidisciplinary services for life sciences clients. We advise clients across the full spectrum of their business lifecycles, ranging from formation, corporate governance, and compliance operations for start-ups, to collaboration, licensing, commercialization, and filing in the business development phase, including initial public offerings, equity financings, and bond/note issuances, as well as domestic and cross-border mergers and acquisitions, asset restructuring, equity incentive plans, and privatizations.
